Francisco J Hernandez-Ilizaliturri

Francisco J Hernandez-Ilizaliturri

UNVERIFIED PROFILE

Are you Francisco J Hernandez-Ilizaliturri?   Register this Author

Register author
Francisco J Hernandez-Ilizaliturri

Francisco J Hernandez-Ilizaliturri

Publications by authors named "Francisco J Hernandez-Ilizaliturri"

Are you Francisco J Hernandez-Ilizaliturri?   Register this Author

67Publications

1685Reads

50Profile Views

Mechanisms of Resistance to Monoclonal Antibodies (mAbs) in Lymphoid Malignancies.

Curr Hematol Malig Rep 2019 Oct;14(5):426-438

Department of Medical Oncology, Roswell Park Comprehensive Cancer Center, Buffalo, NY, 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11899-019-00542-8DOI Listing
October 2019

Dose reductions in ibrutinib therapy are not associated with inferior outcomes in patients with chronic lymphocytic leukemia (CLL).

Leuk Lymphoma 2019 Jul 2;60(7):1650-1655. Epub 2019 Jan 2.

a Department of Medicine , State University of New York at Buffalo , Buffalo , NY , USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428194.2018.1554862DOI Listing
July 2019

Radiological imaging and bone marrow biopsy in staging of cutaneous B-cell lymphoma.

Br J Haematol 2019 02 22;184(4):674-676. Epub 2018 Feb 22.

Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15154DOI Listing
February 2019

A Phase II Trial of Rituximab Combined With Pegfilgrastim in Patients With Indolent B-cell Non-Hodgkin Lymphoma.

Clin Lymphoma Myeloma Leuk 2018 01 6;18(1):e51-e60. Epub 2017 Nov 6.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY; Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clml.2017.09.003DOI Listing
January 2018

Breast Implant-Associated Anaplastic Large Cell Lymphoma (ALCL): A Case Report.

Am J Case Rep 2017 May 31;18:605-610. Epub 2017 May 31.

Department of Radiology, Roswell Park Cancer Institute, Buffalo, NY, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5460956PMC
http://dx.doi.org/10.12659/ajcr.903161DOI Listing
May 2017

EZH2 inhibition re-sensitizes multidrug resistant B-cell lymphomas to etoposide mediated apoptosis.

Oncoscience 2016 29;3(1):21-30. Epub 2016 Jan 29.

Department of Pharmacology and Therapeutics, Roswell Park Cancer Institute, Buffalo, NY, USA; Department of Molecular Pharmacology and Cancer Therapeutics, State University of New York at Buffalo, NY, USA.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4751913PMC
http://dx.doi.org/10.18632/oncoscience.288DOI Listing
March 2016

Vorinostat, a histone deacetylase (HDAC) inhibitor, promotes cell cycle arrest and re-sensitizes rituximab- and chemo-resistant lymphoma cells to chemotherapy agents.

J Cancer Res Clin Oncol 2016 Feb 28;142(2):379-87. Epub 2015 Aug 28.

Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-015-2026-yDOI Listing
February 2016

Ofatumumab Exhibits Enhanced In Vitro and In Vivo Activity Compared to Rituximab in Preclinical Models of Mantle Cell Lymphoma.

Clin Cancer Res 2015 Oct 11;21(19):4391-7. Epub 2015 May 11.

Department of Immunology, Roswell Park Cancer Institute, Buffalo, New York. Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-15-0056DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5685505PMC
October 2015

CD20-negative diffuse large B-cell lymphomas: biology and emerging therapeutic options.

Expert Rev Hematol 2015 Jun 1;8(3):343-54. Epub 2015 Feb 1.

Division of Hematologic Malignancies, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave, M221, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/17474086.2015.1007862DOI Listing
June 2015

Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents.

Br J Haematol 2015 May 23;169(4):506-19. Epub 2015 Feb 23.

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA; Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13318DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802357PMC
May 2015

Novel therapeutic strategies for cutaneous T-cell lymphoma in advanced stages.

Semin Hematol 2014 Jan 14;51(1):35-41. Epub 2013 Nov 14.

Division of Hematology/Oncology(,) Vanderbilt-Ingram Cancer Center, Nashville, TN. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.seminhematol.2013.11.004DOI Listing
January 2014

Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.

J Clin Oncol 2013 Nov 16;31(32):4132-9. Epub 2013 Sep 16.

Andrew M. Evens, Tufts University School of Medicine, Boston; Aimee Kroll-Desrosiers, University of Massachusetts Medical School, Worcester, MA; Ranjana Advani and Stavroula Otis, Stanford University Medical Center, Stanford, CA; Oliver W. Press and Linda M. Parker, Fred Hutchinson Cancer Research Center, Seattle, WA; Izidore S. Lossos, Liat Nadav Dagan, and Jose Sandoval, University of Miami School of Medicine, Miami, FL; Julie M. Vose, University of Nebraska Medical Center, Omaha, NE; Francisco J. Hernandez-Ilizaliturri, Roswell Park Cancer Institute, Buffalo; Ramsey Abdallah and John P. Leonard, Weill Cornell Medical College, New York, NY; Barrett K. Robinson, Indiana University School of Medicine, Indianapolis, IN; Jessica L. Yarber and Leo I. Gordon, Northwestern University Feinberg School of Medicine, Chicago, IL; Kristie A. Blum, The Ohio State University, Columbus, OH; Christopher R. Flowers, Emory University, Atlanta, GA; Thomas M. Habermann, Mayo Clinic, Rochester, MN; and Nancy L. Bartlett, Washington University School of Medicine, St. Louis, MO.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.8220DOI Listing
November 2013

Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma.

Clin Cancer Res 2012 Feb 6;18(4):1039-50. Epub 2012 Jan 6.

Department of Immunology and Medical Oncology, Roswell Park Cancer Institute, Buffalo, New York, NY 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-1429DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3288324PMC
February 2012

Clinical spectrum and prognosis of follicular lymphoma with blastoid transformation: case series and a review of the literature.

Ann Hematol 2011 Aug 1;90(8):955-62. Epub 2011 Feb 1.

Department of Internal Medicine, State University of New York at Buffalo, Elm and Carlton Streets, Buffalo, NY, 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00277-011-1162-yDOI Listing
August 2011

The emerging role of lenalidomide in the management of lymphoid malignancies.

Ther Adv Hematol 2011 Feb;2(1):45-53

Medical Oncology and Immunology, Roswell Park Cancer Institute (RPCI), Buffalo, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/2040620710390547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3573391PMC
February 2011

Novel disease targets and management approaches for diffuse large B-cell lymphoma.

Leuk Lymphoma 2010 Aug;51 Suppl 1:1-10

Metabolism Branch, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3109/10428194.2010.500045DOI Listing
August 2010

Diffuse large B-cell lymphoma presenting as pancoast tumor.

J Clin Oncol 2010 Jun 12;28(16):e254-6. Epub 2010 Apr 12.

Department of Medicine, Roswell Park Cancer Institute, University of Buffalo, NY, USA.

View Article

Download full-text PDF

Source
http://jco.ascopubs.org/content/28/16/e254.full.pdf
Web Search
http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2009.26.1925
Publisher Site
http://dx.doi.org/10.1200/JCO.2009.26.1925DOI Listing
June 2010

Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies.

Curr Opin Investig Drugs 2009 Jun;10(6):579-87

Roswell Park Cancer Institute, Department of Medicine and Immunology, Elm and Carlton Streets, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

Source
June 2009

Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 2. Novel therapeutic strategies.

Oncology (Williston Park) 2009 Jun;23(7):610-5

Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.

View Article

Download full-text PDF

Source
http://ac.els-cdn.com/S0305737214001455/1-s2.0-S030573721400
Web Search
http://search.proquest.com/openview/2a11a7c394c553593a6a3c7b
Web Search
June 2009

Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches.

Oncology (Williston Park) 2009 May;23(6):546-53

Lymphoma/Myeloma Service, Department of Medicine, Roswell Park Cancer Institute, Buffalo, New York, USA.

View Article

Download full-text PDF

Source
May 2009

The use of galiximab in non-Hodgkin lymphoma.

Clin Lymphoma Myeloma 2008 Oct;8(5):277-82

Medical Oncology, Roswell Park Cancer Institute, Buffalo, NY 14202, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3816/CLM.2008.n.038DOI Listing
October 2008

Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression.

Clin Cancer Res 2008 Mar;14(5):1550-60

Departments of Immunology and Medicine, Roswell Park Cancer Institute, Buffalo, New York 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-1255DOI Listing
March 2008

Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.

Clin Cancer Res 2007 Aug;13(15 Pt 1):4556-64

School of Medicine, State University of New York at Buffalo, Buffalo, New York, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-07-0680DOI Listing
August 2007

Primary esophageal lymphoma: case series and review of the literature.

Dig Dis Sci 2006 Jan;51(1):77-83

Department of Internal Medicine, School of Medicine, State University of New York at Buffalo, Buffalo, New York 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10620-006-3088-0DOI Listing
January 2006

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.

Clin Cancer Res 2005 Aug;11(16):5984-92

Department of Medicine , Roswell Park Cancer Institute Buffalo, New York 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-05-0577DOI Listing
August 2005

Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.

Clin Adv Hematol Oncol 2004 Sep;2(9):606-18

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

Source
September 2004

Multimodality therapy for thymic carcinoma (TCA): results of a 30-year single-institution experience.

Am J Clin Oncol 2004 Feb;27(1):68-72

Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.coc.0000046301.83671.09DOI Listing
February 2004

Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.

Clin Cancer Res 2003 Dec;9(16 Pt 1):5866-73

Department of Medicine, Roswell Park Cancer Institute Buffalo, New York 14263, USA.

View Article

Download full-text PDF

Source
December 2003